128 related articles for article (PubMed ID: 19995332)
21. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
Shimoda K; Morita S; Hirokane G; Yokono A; Someya T; Takahashi S
Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
[TBL] [Abstract][Full Text] [Related]
22. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
23. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
24. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
[TBL] [Abstract][Full Text] [Related]
26. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
27. Pinoline may be used as a probe for CYP2D6 activity.
Jiang XL; Shen HW; Yu AM
Drug Metab Dispos; 2009 Mar; 37(3):443-6. PubMed ID: 19095720
[TBL] [Abstract][Full Text] [Related]
28. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
Evert B; Eichelbaum M; Haubruck H; Zanger UM
Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
[TBL] [Abstract][Full Text] [Related]
29. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
30. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Komura H; Iwaki M
Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
[TBL] [Abstract][Full Text] [Related]
32. Effect of venlafaxine on imipramine metabolism.
Albers LJ; Reist C; Vu RL; Fujimoto K; Ozdemir V; Helmeste D; Poland R; Tang SW
Psychiatry Res; 2000 Nov; 96(3):235-43. PubMed ID: 11084219
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
35. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
Lee SY; Ki CS; Hong KS; Kim JW
J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
[TBL] [Abstract][Full Text] [Related]
36. Lack of desipramine toxicity with citalopram.
Ashton AK
J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
[No Abstract] [Full Text] [Related]
37. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
38. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
40. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]